Worse impact of PsA and associated comorbidities on QoL

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.